In 2023, the projected incidence rate of breast cancer in the Australian population was around *** cases per 100,000 in the ** to ** age group, an incidence rate higher than any other age group. In contrast, zero cases per 100,000 people were projected to be diagnosed amongst children aged 14 and below that year.

In 2024, the age-standardized mortality rate from breast cancer for women in Australia was estimated to be **** out of 100,000 women. The rate for men is significantly lower at *** out of 100,000 men.

This dataset presents the footprint of participation statistics in BreastScreen Australia for women ages 50 to 74, by age group. The national breast cancer screening program, BreastScreen Australia began in 1991. It aims to reduce illness and death from breast cancer using screening mammography for early detection of unsuspected breast cancer in women. The data spans the years of 2014-2016 and is aggregated to Statistical Area Level 3 (SA3) geographic boundaries from the 2011 Australian Statistical Geography Standard (ASGS). Cancer is one of the leading causes of illness and death in Australia. Cancer screening programs aim to reduce the impact of selected cancers by facilitating early detection, intervention and treatment. Australia has three cancer screening programs: BreastScreen Australia National Cervical Screening Program (NCSP) National Bowel Cancer Screening Program (NBCSP) The National cancer screening programs participation data presents the latest cancer screening participation rates and trends for Australia's 3 national cancer screening programs. The data has been sourced from the Australian Institute of Health and Welfare (AIHW) analysis of National Bowel Cancer Screening Program register data, state and territory BreastScreen Australia register data and state and territory cervical screening register data. For further information about this dataset, visit the data source:Australian Institute of Health and Welfare - National Cancer Screening Programs Participation Data Tables. Please note: AURIN has spatially enabled the original data.

This statistic shows the age-specific breast cancer mortality rate in Australia in 2016. That year, about ***** out of every 100,000 people aged 85 years or older in Australia died from breast cancer.

In 2020, Australia/New Zealand was the region with the highest incidence rate of breast cancer worldwide, with around 95.5 new cases per 100,000 women. This statistic shows the age-standardized incident rate (new cases) of breast cancer among women worldwide, by region.

The Australian mammography market, valued at approximately $69.28 million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 9.27% from 2025 to 2033. This expansion is fueled by several key factors. Rising prevalence of breast cancer, coupled with increased awareness of early detection and screening programs, significantly drives market demand. Technological advancements, such as the introduction of digital mammography systems, breast tomosynthesis, and AI-powered image analysis, are enhancing diagnostic accuracy and efficiency, further stimulating market growth. The growing geriatric population in Australia, representing a higher-risk demographic for breast cancer, also contributes to increased screening rates and consequently market expansion. The presence of well-established healthcare infrastructure, including numerous hospitals, specialty clinics, and diagnostic centers, provides a strong foundation for market growth. Furthermore, government initiatives promoting preventative healthcare and funding for advanced imaging technologies are likely to accelerate market expansion in the coming years. Competition within the Australian mammography market is relatively high, with established players like Canon Medical Systems, Fujifilm, GE Healthcare, Philips, and Siemens Healthineers dominating the landscape. These companies are actively involved in research and development, focusing on innovation in system design, image quality enhancement, and software solutions. The emergence of smaller, specialized companies offering advanced technologies, such as tomosynthesis and AI-based solutions, is further shaping the competitive dynamics. However, factors such as high equipment costs, the need for skilled professionals for operation and interpretation, and the potential for reimbursement challenges could pose some restraints to market growth. The market segmentation by product type (digital, analog, tomosynthesis, others) and end-user (hospitals, clinics, diagnostic centers) reflects the diverse needs and operational models within the Australian healthcare system. The forecast period of 2025-2033 offers significant opportunities for market participants to capitalize on the growing demand for advanced mammography services in Australia. Recent developments include: In July 2021, breast cancer screening and diagnostic company BCAL diagnostics were listed on the Australian securities exchange following an initial public offering that raised USD 10 million from investors., In June 2021, Keiron's ai breast screening solution MIA received regulatory clearance in Australia. With patented AI technology developed on more than 3 million breast images, MIA (mammography intelligent assessment) is designed to support breast radiologists in deciding whether or not to recall women for further testing based on their mammography screening.. Key drivers for this market are: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging. Potential restraints include: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging. Notable trends are: Diagnostic Centers are Expected to Witness Steady Growth Over the Forecast Period.

The size of the Australia Mammography Market was valued at USD 69.28 Million in 2023 and is projected to reach USD 128.86 Million by 2032, with an expected CAGR of 9.27% during the forecast period. The Australia mammography market is expected to grow steadily due to the growing awareness of breast cancer and the need for early detection. Because breast cancer still remains one of the leading cancers affecting women all over Australia, proper screening programs must be established to enhance the survival chances of most of the affected women. The national screening programs launched by the Australian government urge more women between 50 and 74 years to go for regular mammograms and thus raise the demand for mammographic services. Technological advances, such as digital mammography and 3D tomosynthesis, have improved the accuracy and effectiveness of screenings. Such innovations enhance the detection of tumors with fewer false positives and fewer cases of biopsy, which is always more beneficial to the patient. Artificial intelligence in mammography allows the easy analysis of images and helps radiologists in making the correct diagnosis. Challenges still abound. The disparity between urban and rural access to mammography services and continued public education about the benefits of regular screening all do not negate the change in positive outlook. Budget-constrained healthcare systems can also restrict availability of advanced technologies. The future of the mammography market in Australia appears very promising with ongoing investments in health infrastructure and, above all, commitment to improving the outcomes for breast cancer. It is expected that with the continued running of campaigns to raise awareness and implementation of newer technology systems, the market will increase further and more women in Australia will gain access to early detection and treatment. Recent developments include: In July 2021, breast cancer screening and diagnostic company BCAL diagnostics were listed on the Australian securities exchange following an initial public offering that raised USD 10 million from investors., In June 2021, Keiron's ai breast screening solution MIA received regulatory clearance in Australia. With patented AI technology developed on more than 3 million breast images, MIA (mammography intelligent assessment) is designed to support breast radiologists in deciding whether or not to recall women for further testing based on their mammography screening.. Key drivers for this market are: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging. Potential restraints include: Risk of Adverse Effects from Radiation Exposure. Notable trends are: Diagnostic Centers are Expected to Witness Steady Growth Over the Forecast Period.

Population cohort of women, unaffected and affected by breast cancer, to investigate aspects of breast cancer risk and other important women's health issues. Collection of epidemiological information, mammogram images, breast cancer pathology data. Participants donate DNA and archival breast tumours are collected. Annual registry linkage to confirm cancer diagnoses and mortality data.

Australia Mammography Market size was valued at USD 285 Million in 2024 and is projected to reach USD 495 Million by 2032 growing at a CAGR of 7.1% from 2025 to 2032.

Australia Mammography Market Dynamics

The key market dynamics that are shaping the Australia mammography market include:

Key Market Drivers

Rising Breast Cancer Incidence: According to Cancer Council Australia, breast cancer is the most frequent cancer among Australian women, with roughly 20,000 new cases diagnosed each year. The rising incidence of breast cancer is increasing the demand for early detection via mammography screening.

Around ** in every 100,000 Australians were projected to be diagnosed with melanoma, a type of skin cancer, in 2023. The incidence rate increased with age, with the *****-year-old age group having an estimated incidence of over *** cases per 100,000 persons in 2023.

Incidence of cancer in Australia

Cancer incidence refers to the number of newly diagnosed cases of the disease in a particular time period, typically one year. Cancer is among the leading causes of illness and death in Australia. The types of cancer with the highest incidence in Australia include prostate, breast, colorectal/bowel, melanoma, and lung cancer.

The dark side of the sunny life Down Under

Australia and New Zealand are home to the highest incidence rates of melanoma in the world. Melanoma is a type of skin cancer that is commonly, however not exclusively, found on sun-exposed parts of the body, as the risk of developing melanoma increases with ultra-violet radiation (UV rays). Other types of skin cancers exist, however, melanoma is considered to be the most dangerous given its likelihood of spreading within the body.

The number of females who participated in a breast cancer screening program and there proportion of the relevant population, as well as the number of people diagnosed with breast cancer as a rate of those who participated, 2010-2011 (NSW, Vic, Qld, SA & WA). Source: Compiled by PHIDU based on data from BreastScreen NSW, BreastScreen Vic, BreastScreen Qld, BreastScreen WA - 2010 and 2011.The Dataset also contains the number of females who participated in a cervical cancer screening program and there proportion of the relevant population, as well as the number of the people diagnosed with low/high cervical cancer as a rate of those who participated, 2010-2011 (NSW, Vic, Qld, SA, WA & ACT). Source: Compiled by PHIDU based on data from the NSW Department of Health and NSW Central Cancer Registry, 2011 and 2012; Victorian Cervical Cytology Registry, 2011 and 2012; Queensland Health Cancer Services Screening Branch, 2011 and 2012; SA Cervix Screening Program, 2011 and 2012; Western Australia Cervical Cytology Register, 2011 and 2012; and ACT Cytology Register, 2011 and 2012.For both sets of screening if a women was screened more than twice in the two year period she is counted once only (all entries that were classified as not shown, not published or not applicable were assigned a null value; no data was provided for Maralinga Tjarutja LGA, in South Australia). The data is by LGA 2015 profile (based on the LGA 2011 geographic boundaries). For more information on statistics used please refer to the PHIDU website, available from: http://phidu.torrens.edu.au/

In Australia Breast Cancer Drug Market , was valued at approximately USD 10.11 billion in 2022 and is projected to reach USD 12.45 billion by 2029, registering a Compound Annual Growth Rate (CAGR) of 8.65% during the forecast period.

In 2023, an estimated 3,255 females and 36 males died from breast cancer in Australia. Overall, the number of deaths from breast cancer among males and females in Australia has trended upwards over time since 1978.

This dataset presents the footprint of cancer incidence statistics in Australia for all cancers combined and the 5 top cancer groupings (breast - female only, colorectal, lung, melanoma of the skin and prostate) and their respective ICD-10 codes. The data spans the years 2006-2010 and is aggregated to Statistical Area Level 3 (SA3) from the 2011 Australian Statistical Geography Standard (ASGS).

Incidence data refer to the number of new cases of cancer diagnosed in a given time period. It does not refer to the number of people newly diagnosed (because one person can be diagnosed with more than one cancer in a year). Cancer incidence data come from the Australian Institute of Health and Welfare (AIHW) 2012 Australian Cancer Database (ACD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Cancer Database 2012 Data Quality Statement.

Please note:

• AURIN has spatially enabled the original data.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a SA3. The number of people who could not be assigned a SA3 is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• The ACD records all primary cancers except for basal and squamous cell carcinomas of the skin (BCCs and SCCs). These cancers are not notifiable diseases and are not collected by the state and territory cancer registries.

• The diseases coded to ICD-10 codes D45-D46, D47.1 and D47.3-D47.5, which cover most of the myelodysplastic and myeloproliferative cancers, were not considered cancer at the time the ICD-10 was first published and were not routinely registered by all Australian cancer registries. The ACD contains all cases of these cancers which were diagnosed from 1982 onwards and which have been registered but the collection is not considered complete until 2003 onwards.

• Note that the incidence data presented are for 2006-2010 because 2011 and 2012 data for NSW and ACT were not able to be provided for the 2012 ACD.

BRA-STRAP was launched in 2015 to address a significant need to move from single gene testing in clinical genetics services to evidence-based gene panel tests for breast cancer susceptibility.Since 1997, genetic testing of the BRCA1 and BRCA2 genes had been offered to selected women attending clinical genetics services throughout Australia. For the vast majority of women (~80%) these tests were uninformative (ie negative). Continued research had identified additional breast cancer susceptibility genes and commercial and direct-to-the-public diagnostic testing facilities were including a larger number of genes in gene panel tests made possible via new, massively parallel sequencing technology. These tests posed considerable challenges to clinical genetics services as very little was known about the cancer risks associated with any of the observed genetic variation.The community urgently needed the evidence from which to translate information about these new and putative breast cancer genes into clinical genetics services and to transition to routinely applying gene panel tests.BRA-STRAP conducted a large nation-wide study of women at high-risk of breast cancer who had tested negative for pathogenic variants in BRCA1 and BRCA2. BRA-STRAP designed a 24 gene panel test that included ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, FANCM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, STK11 and TP53. This work brought together data representing 30,000 Australian women of all ages across the cancer risk spectrum, affected and unaffected with breast cancer, and their families. Contributing to BRA-STRAP are i) large research cohorts of aging populations and of women above population risk, and ii) the clinical genetics community and women found negative for BRCA1 and BRCA2 mutations following testing in an Australian Familial Cancer Centre over the last 2 decades. The data enabled Australian population-specific estimates of penetrance and prevalence to be made for several new breast cancer genes that now support the best practice guidelines for genetic testing and risk management for PALB2, ATM and CHEK2 on eviQ (Cancer Treatments Online https://www.eviq.org.au). Pooling with other similar international studies will support further refinement of cancer risk estimates for other genes.

Component one: Literature review to understand issues pertinent to women presenting for breast re-screening. The review includes an examination of (1) studies measuring the prevalence of mammography rescreening; (2) studies exploring factors contributing to returning for repeat screening; and (3) studies examining what the factors and intervention strategies that facilitate or encourage women to return for repeat mammograms. Key words and parameters used: Key words: mammog$ and rescreen$, re-screen$, repeat screen$ re-attend$ reattend$. Limited to 1990-2005. Number of articles identified: 64 Component two: Formative research using focus groups to identify attitudes and beliefs regarding mammography. Results used to develop appropriate counterfactual messages for the project's intervention. Participant surveys, women 50-69 years of age. Component three: A community intervention consisting of two phases. Community Study 1 designed to test whether counterfactual messages resonated with the target audience (how this impacted on self-efficacy). Community study 2 designed to compare the self-efficacy and intentions of women to present for re-screening when presented with counterfactual messages. Survey data and follow up telephone interview. Component four: Collaboration with BreastScreen NSW, an intervention to ascertain the impact of counterfactual messages on behaviour - actual presentations for mammography screening. BreastScreen NSW participant survey.

The Asia-Pacific cancer biomarkers market is experiencing robust growth, driven by rising cancer incidence rates, increasing awareness of early detection and personalized medicine, and substantial investments in research and development within the region. The market's Compound Annual Growth Rate (CAGR) of 12.50% from 2019 to 2024 suggests a significant expansion, expected to continue through 2033. Key drivers include the increasing prevalence of cancers such as prostate, breast, lung, colorectal, and cervical cancers across the region. Furthermore, advancements in biomarker technologies, particularly OMICS technologies and immunoassays, are fueling market growth by enabling more accurate and efficient cancer diagnosis and treatment monitoring. While data on specific regional market shares for China, Japan, India, Australia, and South Korea are unavailable, we can infer that China and India, with their large populations and increasing healthcare expenditure, likely represent significant portions of the market. The segment of protein and genetic biomarkers is likely leading the market due to their established clinical utility. However, challenges remain, including high testing costs, regulatory hurdles for new biomarker technologies, and uneven healthcare infrastructure across the region, potentially acting as restraints on overall market expansion. Despite these challenges, the continued focus on improving cancer care and the promising advancements in biomarker technology are positioning the Asia-Pacific region for substantial growth in the cancer biomarkers market over the next decade. The competitive landscape is marked by a mix of established global players like Abbott Laboratories, Thermo Fisher Scientific, and Roche, alongside emerging regional companies. These companies are actively engaged in developing and commercializing innovative biomarker assays and technologies, further fueling market growth. Strategic partnerships and collaborations are also becoming increasingly prevalent as companies seek to expand their market reach and enhance their product portfolios. Future growth will depend heavily on successful clinical trials demonstrating the efficacy of new biomarker tests, the ongoing development of more sensitive and specific assays, and increased healthcare access in underserved areas across the Asia-Pacific region. The growing acceptance and integration of precision oncology strategies will also be a critical factor in driving future market expansion. Recent developments include: October 2022: The Garvan Institute of Medical Research in Australia discovered a new biomarker for prostate cancer that could lead to better diagnosis and treatment for men with the aggressive form of this disease., February 2022: The University of South Australia used novel biomarkers to decode metastatic breast cancer. They found a connection between aggressive breast cancer cells and the dual CXCR4-CCR7 cell surface protein complexes.. Key drivers for this market are: Rising Prevalence of Cancer, Increasing Research Activities and Growing Usage of Biomarkers in Drug Development. Potential restraints include: Rising Prevalence of Cancer, Increasing Research Activities and Growing Usage of Biomarkers in Drug Development. Notable trends are: Breast Cancer is Expected to Grow with a Significant CAGR in the Market Over the Forecast Period.

Medical Mammography Equipment Market Outlook

The global medical mammography equipment market size was valued at approximately USD 2.1 billion in 2023 and is projected to reach USD 3.9 billion by 2032, growing at a CAGR of 6.5% during the forecast period. This notable growth is primarily driven by advancements in imaging technologies, increased awareness about early breast cancer detection, and rising government initiatives for cancer screening programs.

One of the primary growth factors in the medical mammography equipment market is the increasing prevalence of breast cancer worldwide. Breast cancer remains one of the most common cancers affecting women, and early detection is crucial for effective treatment and improved survival rates. Mammography is considered the gold standard for breast cancer screening, which has led to a significant rise in its adoption. Moreover, advancements in digital technologies and the development of 3D mammography, also known as breast tomosynthesis, have further enhanced the accuracy and efficiency of breast cancer diagnosis, driving market growth.

Technological advancements in mammography equipment have also played a significant role in market expansion. The transition from analog to digital mammography has revolutionized breast imaging by providing higher resolution images, reducing radiation exposure, and enabling better storage and retrieval of patient data. Additionally, the advent of 3D mammography has addressed many limitations of traditional 2D mammography by offering more detailed images and reducing false positives and call-back rates. These innovations have significantly improved the diagnostic capabilities of healthcare providers, further boosting the demand for advanced mammography equipment.

Government initiatives and screening programs are another critical factor contributing to the growth of the medical mammography equipment market. Many countries have implemented national breast cancer screening programs to facilitate early detection and improve patient outcomes. For instance, programs such as BreastScreen Australia, the National Breast Screening Program in the UK, and the Breast Cancer Screening Program in the US have significantly increased the adoption of mammography equipment. These initiatives, coupled with rising awareness campaigns, have encouraged more women to undergo regular screenings, thus driving market growth.

Mammography, as a critical tool in breast cancer screening, has evolved significantly over the years. It remains the cornerstone of early detection strategies, offering a non-invasive method to identify potential abnormalities in breast tissue. The process involves using low-dose X-rays to create detailed images of the breast, which radiologists analyze for any signs of cancer. With the advent of digital technologies, mammography has become more efficient, providing clearer images and reducing the need for repeat scans. This evolution not only enhances diagnostic accuracy but also increases patient comfort and reduces anxiety associated with the screening process.

Regionally, the market for medical mammography equipment is witnessing significant growth across various geographies. North America holds the largest market share, attributed to the high prevalence of breast cancer, well-established healthcare infrastructure, and extensive government support for breast cancer screening programs. Europe follows closely, driven by similar factors and a growing emphasis on early diagnosis. The Asia Pacific region is expected to exhibit the highest growth rate during the forecast period, fueled by increasing awareness, rising healthcare expenditure, and expanding screening initiatives in countries like China and India. Latin America and the Middle East & Africa are also anticipated to experience steady growth, supported by improving healthcare infrastructure and growing awareness about breast cancer detection.

Product Type Analysis

In the product type segment, digital mammography stands out as the most significant contributor to the medical mammography equipment market. Digital mammography, which includes Full Field Digital Mammography (FFDM), offers superior image quality, reduced radiation dose, and enhanced diagnostic accuracy compared to analog systems. The transition from analog to digital has been a game-changer, enabling healthcare providers to detect breast cancer at earlier stages, thus improving treatment outcomes. The convenience of storing and sharing digital images also provides an

This dataset presents the footprint of female cancer mortality statistics in Australia for all cancers combined and the 11 top cancer groupings (breast, cervical, colorectal, leukaemia, lung, lymphoma, melanoma of the skin, ovary, pancreas, thyroid and uterus) and their respective ICD-10 codes. The data spans the years 2009-2013 and is aggregated to Greater Capital City Statistical Areas (GCCSA) from the 2011 Australian Statistical Geography Standard (ASGS).

Mortality data refer to the number of deaths due to cancer in a given time period. Cancer deaths data are sourced from the Australian Institute of Health and Welfare (AIHW) 2013 National Mortality Database (NMD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Institute of Health and Welfare - 2013 National Mortality Database.

Please note:

• AURIN has spatially enabled the original data.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a GCCSA. The number of people who could not be assigned a GCCSA is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• Cause of Death Unit Record File data are provided to the AIHW by the Registries of Births, Deaths and Marriages and the National Coronial Information System (managed by the Victorian Department of Justice) and include cause of death coded by the Australian Bureau of Statistics (ABS). The data are maintained by the AIHW in the NMD.

• Year refers to year of occurrence of death for years up to and including 2012, and year of registration of death for 2013. Deaths registered in 2011 and earlier are based on the final version of cause of death data; deaths registered in 2012 and 2013 are based on revised and preliminary versions, respectively and are subject to further revision by the ABS.

• Cause of death information are based on underlying cause of death and are classified according to the International Classification of Diseases and Related Health Problems (ICD). Deaths registered in 1997 onwards are classified according to the 10th revision (ICD-10).

• Colorectal deaths presented are underestimates. For further information, refer to "Complexities in the measurement of bowel cancer in Australia" in Causes of Death, Australia (ABS cat. no. 3303.0).

The size of the Asia-Pacific Cancer Biomarkers Industry market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 12.50% during the forecast period. An Asia-Pacific Cancer Biomarkers Industry represents a developing industry, providing a lot of support to the detection and diagnosis of early treatment. A cancer biomarker is a specific type of molecule that includes proteins, genes, or metabolites that indicate cancer presence or progression in the body. Biomarkers are found within biological samples such as blood, urine, tissue, and other body fluids. The employment of cancer biomarkers has revolutionized the field of oncology because it leads to earlier and more accurate diagnosis of cancer. What had thus far been applied towards the diagnosis of cancer include imaging and biopsies, which are invasive and also take longer to produce results. Early detection of cancer through biomarkers can therefore benefit in terms of treatment outcomes or survival chances because the test is not invasive-that is just the blood draw. In addition to the diagnosis mentioned above, cancer biomarkers have diverse application in monitoring of diseases progression, treatment evaluation and identification of therapeutic targets. The health care providers can monitor changes in the level of biomarkers over time to assess the effectiveness of treatments hence make necessary changes in the treatments. Biomarkers are also capable of diagnosing at-risk patients to develop or recur cancer so that appropriate preventive and surveillance strategies can be carried out on them. The Asia-Pacific region is steadily increasing its demand for cancer biomarkers: incidence of the disease, awareness of early stages, and scientific advancement. And because of a huge population and increasing healthcare infrastructure, the industry would grow in that region. Scientific innovation and interactions between researchers, health providers, and industrialists are enhancing the development of new biomarkers at a faster rate. The Asia-Pacific Cancer Biomarkers Industry is one of the most vibrant sectors with vast potential. Biomarkers for cancer are a very significant tool in the early detection, diagnosis, and management of cancer. Given that this region continues to invest in more research and development, we can expect further advancements into biomarker technology, yielding far better outcomes for the patients suffering from cancer. Recent developments include: October 2022: The Garvan Institute of Medical Research in Australia discovered a new biomarker for prostate cancer that could lead to better diagnosis and treatment for men with the aggressive form of this disease., February 2022: The University of South Australia used novel biomarkers to decode metastatic breast cancer. They found a connection between aggressive breast cancer cells and the dual CXCR4-CCR7 cell surface protein complexes.. Key drivers for this market are: Rising Prevalence of Cancer, Increasing Research Activities and Growing Usage of Biomarkers in Drug Development. Potential restraints include: High Cost of Diagnosis, Reimbursement Issues. Notable trends are: Breast Cancer is Expected to Grow with a Significant CAGR in the Market Over the Forecast Period.